Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients
- PMID: 26239059
- DOI: 10.1111/jth.13065
Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients
Abstract
Background: Local fluid dynamics and exposed atherosclerotic lesions regulate thrombus formation. Activated cells in the attached thrombi release microparticles to the circulation (circulating microparticles [cMPs]); however, their phenotype is unknown.
Objectives: To investigate the specific phenotype of the cMPs released by growing thrombi.
Methods/patients: cMPs released by thrombi growing in different well-characterized thrombogenic conditions were investigated. cMP contents just before and immediately after perfusion of the thrombogenic surfaces were analyzed by triple-labeling flow cytometry. cMPs were tested for their thrombin-generating capacity. The cMPs identified in the ex vivo perfusion experiments were validated in blood of ST-elevation myocardial infarction (STEMI) patients undergoing thrombectomy and percutaneous coronary intervention. Culprit coronary blood (STEMI-CCB) and peripheral artery blood (STEMI-PAB) were simultaneously analyzed and compared with peripheral artery blood from age-matched controls (C-PAB) and peripheral artery blood from patients who had recovered from acute coronary syndrome (ACS) (pSTEMI-PAB).
Results: The levels of annexin V(+) cMPs significantly increased in blood collected after perfusion of the exposed thrombogenic surfaces. cMP release was directly related to the formed thrombus mass and the plasma procoagulant activity. Post-thrombus blood showed higher thrombin generation potential and contained higher levels of cMPs carrying glycophorin-A (CD235a(+) ; erythrocyte-derived microparticles [ErMPs]) than preperfusion blood (P < 0.05), whereas the levels of cMPs carrying activated and adhesion platelet markers were decreased. STEMI-CCB and STEMI-PAB had significantly higher ErMP levels than control blood (P < 0.005). ErMP levels were also significantly higher in STEMI-PAB than in pSTEMI-PAB, validating the experimental mechanistic studies and suggesting that ErMPs are markers of ongoing coronary thrombosis (C-statistics: 0.950; 95% confidence interval 0.889-1.000; P < 0.001).
Conclusion: Glycophorin-A-rich microparticles are released from evolving growing thrombi into the distal perfusing blood, and can be measured in peripheral blood. CD235a(+) cMPs may constitute a novel systemic biomarker of ongoing thrombosis.
Keywords: blood platelets; cell-derived microparticles; erythrocytes; hemodynamics; thrombosis.
© 2015 International Society on Thrombosis and Haemostasis.
Similar articles
-
Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time.Int J Cardiol. 2016 Jan 1;202:378-87. doi: 10.1016/j.ijcard.2015.09.011. Epub 2015 Sep 12. Int J Cardiol. 2016. PMID: 26432487
-
Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity.PLoS One. 2017 Feb 16;12(2):e0172558. doi: 10.1371/journal.pone.0172558. eCollection 2017. PLoS One. 2017. PMID: 28207887 Free PMC article.
-
Circulating microparticles are associated with clinical severity of persistent ST-segment elevation myocardial infarction complicated with cardiogenic shock.Int J Cardiol. 2018 May 1;258:249-256. doi: 10.1016/j.ijcard.2017.10.044. Int J Cardiol. 2018. PMID: 29544939
-
Thrombus aspiration therapy and coronary thrombus components in patients with acute ST-elevation myocardial infarction.J Atheroscler Thromb. 2013;20(6):524-37. doi: 10.5551/jat.17608. Epub 2013 Apr 30. J Atheroscler Thromb. 2013. PMID: 23629150 Review.
-
Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles.Crit Rev Clin Lab Sci. 2017 Jan;54(1):49-58. doi: 10.1080/10408363.2016.1241214. Epub 2016 Dec 26. Crit Rev Clin Lab Sci. 2017. PMID: 28013562 Review.
Cited by
-
Production of erythrocyte microparticles in a sub-hemolytic environment.J Artif Organs. 2021 Jun;24(2):135-145. doi: 10.1007/s10047-020-01231-7. Epub 2021 Jan 9. J Artif Organs. 2021. PMID: 33420875
-
Circulating Platelet-Derived Microparticles Associated with Postdischarge Major Adverse Cardiac Events in ST-Elevation Acute Myocardial Infarction.Cardiol Res Pract. 2020 Jul 6;2020:6721584. doi: 10.1155/2020/6721584. eCollection 2020. Cardiol Res Pract. 2020. PMID: 32695505 Free PMC article.
-
Sensitive and Specific Detection of Platelet-Derived and Tissue Factor-Positive Extracellular Vesicles in Plasma Using Solid-Phase Proximity Ligation Assay.TH Open. 2018 Jul 27;2(3):e250-e260. doi: 10.1055/s-0038-1667204. eCollection 2018 Jul. TH Open. 2018. PMID: 31276087 Free PMC article.
-
Association of Acute Hyperglycemia and Diabetes Mellitus with Platelet-derived Microparticle (PDMP) Levels During Acute Myocardial Infarction.J ASEAN Fed Endocr Soc. 2023;38(2):35-40. doi: 10.15605/jafes.038.02.03. Epub 2023 Jul 30. J ASEAN Fed Endocr Soc. 2023. PMID: 38045660 Free PMC article.
-
Extracellular vesicles in atherothrombosis: From biomarkers and precision medicine to therapeutic targets.Immunol Rev. 2022 Nov;312(1):6-19. doi: 10.1111/imr.13127. Epub 2022 Aug 22. Immunol Rev. 2022. PMID: 35996799 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical